Tracked deals
6
6 tracked deals across 2020-2024.
Miami, Florida, United States
Accelmed Partners is a lower middle-market private equity firm focused on acquiring and investing in U.S. commercial-stage HealthTech companies, leveraging healthcare and operational expertise to support growth across medical device, tools, diagnostics, digital health, and tech-enabled services.
Tracked deals
6
6 tracked deals across 2020-2024.
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Growth capital
3 growth capital · 1 addon · 1 buyout
Last 4 years
Supporting Data
Bioventus has signed a definitive agreement to sell the Advanced Rehabilitation business of its subsidiary Bioness to private equity firm Accelmed Partners for total cash consideration of $45 million (including up to $20 million in earn-outs). The divestiture reduces Bioventus' annual revenue by about $50 million and allows Bioventus to focus on its core business while Accelmed plans to invest in and expand the Bioness rehabilitation product line.
Accelmed Partners completed a $35 million growth investment in SKNV Inc., a Florida-based dermatology digital health company and FDA-registered 503B outsourcing facility that supplies customized medications and an ecommerce/in-practice dispensing platform. Proceeds will fund a new manufacturing facility in Florida, scale SKNV's proprietary digital platform, expand its U.S. sales footprint, and add strategic management hires.
Veranex has received strategic growth investments from Accelmed Partners II and Lauxera Capital Partners, joining existing investor Summit Partners, which retains majority ownership. The investments — terms undisclosed — will support Veranex’s continued global expansion and development of its integrated, tech‑enabled medical technology product development services; Uri Geiger (Accelmed) and Samuel Levy (Lauxera) joined Veranex’s board.
Keystone Dental, an Accelmed Partners I portfolio company, acquired Osteon Medical and completed a $25 million financing round led by Nantahala with participation from Accelmed and Migdal. Proceeds will support the Osteon acquisition and fund Keystone's continued growth, including market expansion and investment in its dental implant product portfolio and digital capabilities.
Accelmed Partners led a $40 million growth investment in MedMinder Systems Inc., with participation from Israel-based investor Arkin Holdings and existing shareholders. The capital will be used to expand MedMinder’s connected care and telehealth capabilities, scale commercial operations by opening additional automated pharmacy locations across the U.S., and grow the company’s sales, marketing and management teams.
Accelmed Partners II (AP-II) has completed a buyout of TearLab Corporation, a developer of point-of-care tear diagnostic devices, positioning the company as a private entity to pursue development of its next-generation Discovery platform and targeted acquisitions. The transaction includes a planned investment to support growth, pay down debt, and build a comprehensive dry eye care platform for eyecare professionals and patients.
Turn tracked acquisition activity into an outreach-ready buyer list.